ATE193706T1 - Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität - Google Patents

Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität

Info

Publication number
ATE193706T1
ATE193706T1 AT94810642T AT94810642T ATE193706T1 AT E193706 T1 ATE193706 T1 AT E193706T1 AT 94810642 T AT94810642 T AT 94810642T AT 94810642 T AT94810642 T AT 94810642T AT E193706 T1 ATE193706 T1 AT E193706T1
Authority
AT
Austria
Prior art keywords
lower alkyl
compounds
carbocyclic
aryl
cycloalkyl
Prior art date
Application number
AT94810642T
Other languages
English (en)
Inventor
Cynthia A Fink
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/153,395 external-priority patent/US5432186A/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE193706T1 publication Critical patent/ATE193706T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
AT94810642T 1993-11-16 1994-11-07 Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität ATE193706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/153,395 US5432186A (en) 1993-11-16 1993-11-16 Cyclic amino acid derivatives
US08/263,859 US5506244A (en) 1993-11-16 1994-06-22 Cyclic amino acid derivatives

Publications (1)

Publication Number Publication Date
ATE193706T1 true ATE193706T1 (de) 2000-06-15

Family

ID=26850506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94810642T ATE193706T1 (de) 1993-11-16 1994-11-07 Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität

Country Status (19)

Country Link
US (1) US5668158A (de)
EP (1) EP0655461B1 (de)
JP (1) JP3647914B2 (de)
CN (1) CN1058019C (de)
AT (1) ATE193706T1 (de)
AU (1) AU687444B2 (de)
CA (1) CA2135711A1 (de)
CY (1) CY2234B1 (de)
DE (1) DE69424846T2 (de)
DK (1) DK0655461T3 (de)
ES (1) ES2148305T3 (de)
FI (1) FI118600B (de)
GR (1) GR3033829T3 (de)
HU (1) HU226300B1 (de)
IL (1) IL111581A (de)
NO (1) NO311224B1 (de)
NZ (1) NZ264913A (de)
PH (1) PH31056A (de)
PT (1) PT655461E (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1273455B (it) * 1995-01-27 1997-07-08 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
AU7211696A (en) * 1995-09-27 1997-04-17 Ciba-Geigy Ag Treatment of chronic progressive renal failure
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
EP1073674A1 (de) * 1998-04-23 2001-02-07 Novartis AG Thiol enthaltende inhibitore des endothelin konvertierenden enzyms
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
US6426354B1 (en) 1998-04-23 2002-07-30 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
HUP0200662A3 (en) * 1999-03-29 2004-07-28 Bristol Myers Squibb Company P Use of composition containing vasopeptidase to treat angina pectoris
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
JP4263095B2 (ja) 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Ａｃｅおよびｎｅｐの両阻害剤としてのピラン誘導体
DE60303441T2 (de) 2002-02-08 2006-09-21 Merck & Co., Inc. N-biphenylmethylaminocycloalkancarboxamid-derivative
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
US7045653B2 (en) 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
WO2008084533A1 (ja) * 2007-01-10 2008-07-17 Kowa Co., Ltd. メニエール病治療薬
CN105670160A (zh) * 2015-10-12 2016-06-15 陆思烨 一种防紫外抗老化电线电缆料及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093739A (en) * 1977-06-15 1978-06-06 Mead Johnson & Company Mercaptoacylamidobenzoyl glycine and mucolytic process
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
GB9004260D0 (en) * 1990-02-26 1990-04-18 Pfizer Ltd Therapeutic agents
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
ES2148305T3 (es) 2000-10-16
JPH07196685A (ja) 1995-08-01
PT655461E (pt) 2000-11-30
HU9403276D0 (en) 1995-01-30
CN1058019C (zh) 2000-11-01
DE69424846T2 (de) 2000-11-16
PH31056A (en) 1998-02-03
US5668158A (en) 1997-09-16
EP0655461A1 (de) 1995-05-31
HU226300B1 (en) 2008-08-28
GR3033829T3 (en) 2000-10-31
AU687444B2 (en) 1998-02-26
FI945354A7 (fi) 1995-05-17
NO311224B1 (no) 2001-10-29
IL111581A (en) 1999-07-14
NO944364D0 (no) 1994-11-15
DK0655461T3 (da) 2000-10-02
JP3647914B2 (ja) 2005-05-18
FI118600B (fi) 2008-01-15
EP0655461B1 (de) 2000-06-07
NO944364L (no) 1995-05-18
CA2135711A1 (en) 1995-05-17
AU7772994A (en) 1995-05-25
DE69424846D1 (de) 2000-07-13
CN1107857A (zh) 1995-09-06
NZ264913A (en) 1997-02-24
FI945354A0 (fi) 1994-11-14
CY2234B1 (en) 2003-04-18
IL111581A0 (en) 1995-01-24
HUT71423A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
DE69424846D1 (de) Zyklische Aminosäure-Derivate mit ACE und NEP inhibierender Aktivität
AU551239B2 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro isoquinoline-3-carboxylic acids
KR880007461A (ko) 헤테로 사이클-치환 디포스포네이트화합물 및 이의 약제학적 조성물
DE69207479D1 (de) Verwendung der Ester von Acyl-L-Carnitin mit Gamma-Hydroxy-Buttersäure zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Lebererkrankungen
ATE157348T1 (de) Ester von l-carnitin und acyl-l-carnitin, mit entspannender wirkung, selektiv auf den gastrointestinaltrakt und sie enthaltende pharmazeutische zusammensetzungen
DK599885D0 (da) Trienamidforbindelser og farmaceutisk acceptable salte heraf med antiinflammatorisk og analgetisk virkning samt farmaceutisk komposition indeholdende disse
EP0802179A4 (de) Derivate substituierter amidinonaphthylester
ATE46347T1 (de) Immunostimulierende peptide.
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
FR2757858B1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR910002787A (ko) 아크릴산 아미드유도체, 이들의 제조방법, 이들을 함유하는 약리학적 조성물 및 이들을 사용하는 약품

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee